NDA 208464 · Gilead Sciences INC
Vemlidy
Tenofovir Alafenamide Fumarate · Oral
Last checked: Nov 20, 2026Latest source record: Mar 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Nov 10, 2016
Approved uses
9
Original approval plus efficacy supplements
Registered trials
339
91 Phase 3, 31 recruiting
FAERS reports
4,168
2,952 serious, 436 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Discontinuation of anti-hepatitis B therapy may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely in patients who discontinue VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted. ( 5.1 )
What it is approved for
From the label in effect Jul 14, 2025.
VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease [see Clinical Studies (14) ] . VEMLIDY is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease. ( 1 )
Mechanism: Tenofovir alafenamide is an antiviral drug against the hepatitis B virus [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2024 Supplement 16 · Efficacy · priority review LetterLabel
- Mar 27, 2024 Supplement 17 · Efficacy LetterLabel
- Oct 17, 2022 Supplement 14 · Efficacy · priority review LetterLabel
- Aug 18, 2020 Supplement 10 · Efficacy LetterLabel
- Aug 18, 2020 Supplement 11 · Efficacy LetterLabel
- Feb 4, 2020 Supplement 8 · Efficacy LetterLabel
- Feb 4, 2019 Supplement 7 · Efficacy LabelLetter
- Jul 3, 2018 Supplement 4 · Efficacy Letter
- Nov 10, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
- VEMLIDY · TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tenofovir Alafenamide" as an intervention, any sponsor and status, largest first.
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort ApproachNot yet recruiting
The Task Force for Global HealthAcademic, hospital or other
NCT07258251 · 6,000 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2028
Drug: Tenofovir Alafenamide (TAF) · For: Chronic Hepatitis B; Hepatitis B Virus Infection
Sites: Phichit, Thailand
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT05182463 · 5,000 participants (planned) · Start Jan 8, 2022 · Primary completion Dec 13, 2026
Drug: Peginterferon Alfa-2B; Nucleoside Analogs · For: Hepatitis B, Chronic
Sites: Guangzhou, China
- Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04925752 · 3,292 participants · Start Jun 28, 2021 · Primary completion Aug 21, 2024
Drug: Oral Lenacapavir (LEN); F/TDF and 5 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 93 sites in all
- Study on Screening, Verification and Intervention of High-risk Patients With Liver CancerPivotal-lookingStatus unknown
Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
NCT05721300 · 2,215 participants (planned) · Start Feb 10, 2023 · Primary completion Dec 31, 2024
Drug: NAs("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") combined with interferon treatments; NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide") treatments · For: Hepatocellular Carcinoma; Chronic Hepatitis B
Sites: Xiamen, China
Qing XIeAcademic, hospital or other
NCT06323681 · 2,016 participants (planned) · Start Feb 4, 2024 · Primary completion Feb 2027
Drug: Peginterferon α-2b based treatment group; NAs monotherapy group · For: Chronic Hepatitis b
Sites: Shanghai, China
- A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEPPivotal-lookingCompleted
MRC/UVRI and LSHTM Uganda Research UnitAcademic, hospital or other
NCT04066881 · 1,512 participants · Start Dec 15, 2020 · Primary completion Dec 31, 2024
Drug: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48); Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48) and 3 more · For: HIV Infections
Sites: Entebbe, Uganda
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death254
- product dose omission issue184
- off label use172
- fatigue144
- drug ineffective125
- diarrhoea96
- headache92
- nausea92
- drug interaction89
- product use issue88
- neoplasm malignant72
- rash72
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 108 |
| 2018 | 310 |
| 2019 | 513 |
| 2020 | 413 |
| 2021 | 536 |
| 2022 | 551 |
| 2023 | 510 |
| 2024 | 473 |
| 2025 | 419 |
| 2026 | 331 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vemlidy (Tenofovir Alafenamide)
2024 spending
$199M
Beneficiaries
14,948
128,867 claims
Per beneficiary
$13,312
$47.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $127,209,285 |
| 2021 | $137,298,226 |
| 2022 | $158,415,546 |
| 2023 | $187,858,704 |
| 2024 | $198,986,501 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Bekker LG, Das M, Abdool Karim Q, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis.
Pan CQ, Zhu L, Yu AS, et al. · Clin Infect Dis 2024 · Comparative Study, Systematic Review
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
- Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.
Lim YS, Yu ML, Choi J, et al. · Lancet Gastroenterol Hepatol 2025 · Randomized Controlled Trial, Multicenter Study
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, Molina JM, Thompson MA, et al. · Lancet 2020 · Clinical Trial, Phase III, Comparative Study
- Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Rockstroh JK, Ramgopal MN, Curran Fàbregas A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.